Research programme: single-stranded RNAi therapeutics - Alnylam/IsisAlternative Names: ssRNAi research programme - Alnylam/Isis
Latest Information Update: 22 Mar 2011
At a glance
- Originator Alnylam Pharmaceuticals; Isis Pharmaceuticals
- Class Oligonucleotides; Small interfering RNA
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Apr 2009 Early research in Undefined indication in USA (unspecified route)